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Acute toxicityBased on ethnopharmacological indications that Mentha species may be used in the treatment of gastro-
intestinal diseases, this study aimed to characterize the gastroprotective mechanisms of menthol (ME),
the major compound of the essential oil from species of the genus Mentha. The gastroprotective action
of ME was analyzed in gastric ulcers that were induced by ethanol or indomethacin in Wistar male rats.
The mechanisms responsible for the gastroprotective effect were assessed by analyzing the amount of
mucus secreted, involvement of non-protein sulfhydryl (NP-SH) compounds, involvement of calcium
ion channels and NO/cGMP/K+ATP pathway, gastric antisecretory activity and the prostaglandin E2
(PGE2) production. The anti-diarrheal activity and acute toxicity of ME were also evaluated. Oral treat-
ment with ME (50 mg/kg) offered 88.62% and 72.62% of gastroprotection against ethanol and indometh-
acin, respectively. There was an increased amount of mucus and PGE2 production. The gastroprotective
activity of ME involved NP-SH compounds and the stimulation of K+ATP channels, but not the activation
of calcium ion channels or the production of NO. The oral administration of ME induced an antisecretory
effect as it decreased the H+ concentration in gastric juice. ME displayed anti-diarrheal and antiperistaltic
activity. There were no signs of toxicity in the biochemical analyses performed in the rats’ serum. These
results demonstrated that ME provides gastroprotective and anti-diarrheal activities with no toxicity in
rats.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The gastric mucosa is continuously exposed to damaging agents
that are involved in the pathogenesis of gastric ulcers. These dam-
aging agents can be endogenous (e.g., hydrochloric acid, pepsin, re-
ﬂuxed bile, and reactive oxygen species) or exogenous (e.g., alcohol
consumption, excessive coffee ingestion, and administration of
non-steroidal anti-inﬂammatory drugs). The basic physiopathol-
ogy of gastric ulcers results from an imbalance between damaging
factors and cytoprotective factors, which include an intact mucus
barrier, prostaglandins, adequate mucosal blood ﬂow, activity of
antioxidant compounds, and other mediators, although the exact
ulcer etiology is complex and multifactorial [1].
Gastrointestinal diseases are major public health issues
throughout the world and are estimated to affect 70% of the gen-
eral population [2]. The oral administration of ethanol is widelyused to induce experimental gastric ulcer because it is easily repro-
ducible and rapidly penetrates into the gastric mucosa. Ethanol
causes necrotic lesions of the gastric mucosa in a multifactorial
way. Ethanol is known to induce ulcers in the glandular part of
stomach due to the secretion of mast cell secretory products and
reactive oxygen species [3]. Ethanol also acts by reducing the
secretion of bicarbonate and the production of mucus, thus result-
ing in an increased ﬂow of Na+ and K+, increased pepsin secretion,
and a loss of H+ ions into the lumen [4,5], which leads to cell necro-
sis and ulcer formation. HCl secretion further deepens necrosis and
increases tissue injury. Because of these factors, ethanol-induced
ulcers can be inhibited by agents that enhance mucosal defensive
factors [6,7].
There is a continuous search for a new bioactive compound
derived from medicinal plants and natural products with gastro-
protective and ulcer-healing properties. The new compound
should be accessible, safe, and gastroprotective, and it should
effectively heal the ulcer, thus avoiding its recurrence [8]. Plants
have presented promising results in the treatment of gastric ulcers
in several research projects worldwide [9]. Among the natural
compounds that have been studied in recent studies, several
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[10], suaveolol [11] and carvacrol [12]. Menthol (ME) is a cyclic
terpene with molecular weight 156 kDa and the formula
C10H20O. ME is the main compound of the essential oil from the
species of the genus Mentha and is responsible for giving Mentha
species their distinctive smell and ﬂavor. Among the optical iso-
mers, ()menthol occurs most widely in nature and is endowed
with the peculiar property of being a fragrance and ﬂavor
compound [13]. This study aimed to characterize the mechanism
of action of ME against ethanol- and indomethacin-induced gastric
ulcers in rats. We also sought to evaluate the anti-diarrheal activity
and the acute toxicity induced by ME.2. Materials and methods
2.1. Menthol
()Menthol (catalog #63660) was purchased from Sigma
Chemical Co. (St. Louis, MO, USA).
2.2. Animals
Male Wistar rats (200–250 g) from the Central Animal House of
UNESP were fed a certiﬁed diet with free access to tap water under
standard light–dark cycles (12 h dark–12 h light), humidity
(60 ± 1%) and temperature (21 ± 2 C). All rats were fasted for at
least 16 h prior to each experiment because the treatments were
orally administered. Rats were housed in cages with raised,
wide-mesh ﬂoors to prevent coprophagy. After each experiment,
the rats were euthanized in a CO2 chamber. All experimental pro-
tocols followed the recommendations of the Canadian Council on
Animal Care and were approved by the UNESP Institutional Animal
Care and Use Committee (permit number 221-CEEA, 2010).
2.3. Experimental assays
2.3.1. Ethanol-induced gastric ulcers: determination of dose
Male Wistar rats were distributed into ﬁve groups (n = 7) and
then orally dosed with vehicle (10 mL/kg), carbenoxolone
(100 mg/kg) or ME (25, 50 or 100 mg/kg). After 1 h, the animals re-
ceived an oral dose of 1 mL of absolute ethanol. 1 h after ethanol
treatment, the rats were euthanized, and their stomachs were
removed [14]. The stomachs were then opened along the greater
curvature and washed. The ﬂattened stomach samples were
scanned, and the ulcer area (mm2) was measured using the AVSoft
BioView software. The lower effective dose from the 3 doses tested
was adopted for all other assays.
After scanning, stomach samples were collected for histological
slide preparation and were either stained with hematoxylin and
eosin (HE) or periodic acid-Schiff (PAS). A microscopic score [15]
was determined for the following parameters: epithelial desqua-
mation, hemorrhage, glandular damage, and eosinophilic inﬁltra-
tion. A scale ranging from 0 to 3 (0: none, 1: mild, 2: moderate,
and 3: severe) was used for each criterion. The highest possible
score was 12.
2.3.2. Involvement of the NO/cGMP/K+ATP pathway in
gastroprotection
Rats were distributed into eight groups (n = 7). Two groups of
rats were subjected to intraperitoneal treatment with the follow-
ing drugs: vehicle (8% tween 80, 10 mL/kg), L-NAME (N-nitro-L-
arginine methyl ester 70 mg/kg, a NO synthase inhibitor), ODQ
(1H[1,2,4]oxadiazolo[4,3-a]quinoxaline-1-one 10 mg/kg, a guany-
late cyclase inhibitor) or glibenclamide (K+ATP channel blocker
3 mg/kg). 1 h later, the vehicle (10 mL/kg) and ME (50 mg/kg) wereorally administered to four groups each [16]. After 60 min, all
groups were orally treated with 1 mL of absolute ethanol for gas-
tric ulcer induction. The rats were euthanized 1 h after ethanol
administration, and the stomachs were removed, opened along
the greater curvature, scanned and the ulcer area (mm2) was deter-
mined using the AVSoft BioView software.
2.3.3. Involvement of non-protein sulfhydryl compounds (NP-SH) or
calcium ion channels in gastroprotection
Rats were distributed into six groups (n = 7). Two groups of rats
were subjected to intraperitoneal treatment with the following
drugs: vehicle (8% tween 80, 10 mL/kg), NEM (N-ethylmaleimide
5 mg/kg, a NP-SH compounds blocker) or verapamil (a calcium
channel blocker, 5 mg/kg). 1 h later, the vehicle (10 mL/kg) and
ME (50 mg/kg) were orally administered to three groups each.
After 60 min, all groups were orally treated with 1 mL of absolute
ethanol for gastric ulcer induction. The rats were killed 1 h after
ethanol administration, and the stomachs were removed, opened
along the greater curvature, scanned and the ulcer area (mm2)
was determined using AVSoft BioView.
2.3.4. Evaluation of gastric juice parameters
Rats were randomly divided into six groups (n = 7). 30 min after
oral treatment or immediately after the intra-duodenal adminis-
tration of a single dose of vehicle (10 mL/kg), cimetidine
(100 mg/kg) or ME (50 mg/kg), the rats were subjected to pyloric
ligation [17]. 4 h later, the animals were euthanized, the abdomen
was opened, and another ligature was placed around the esopha-
gus, close to the diaphragm. The stomach was removed, and its
contents were drained into a graduated centrifuge tube, which
was then centrifuged at 2000g for 15 min. The total acid content
of the gastric secretions was determined by titration to pH 7.0 with
0.01 N NaOH using a digital burette. The total concentration of acid
was expressed as mEq/mL/4 h.
2.3.5. Determination of mucus adherence to the gastric wall
After 24 h of fasting, anesthetized rats (n = 7) were subjected to
longitudinal incisions slightly below the xiphoid apophysis for the
placement of a pyloric ligature. The oral administration of vehicle,
carbenoxolone (200 mg/kg) or ME (50 mg/kg) was performed 1 h
before the ligature. After 4 h, the rats were euthanized, and the
glandular portion of the stomach was weighed, and immersed in
Alcian Blue solution for the mucus quantiﬁcation procedure. The
absorbance was measured by ELISA in a spectrophotometer at a
wavelength of 598 nm, and the results were expressed as lg Alcian
Blue/g tissue [18].
2.3.6. Non-steroidal anti-inﬂammatory drug (NSAID)-induced gastric
ulcers
Rats were distributed into three groups (n = 7). Vehicle (10 mL/
kg), cimetidine (100 mg/kg) or ME (50 mg/kg) were orally admin-
istered 30 min prior to the induction of gastric lesions by the oral
administration of the ulcerogenic agent indomethacin (100 mg/
kg). The animals were euthanized 5 h after treatment with indo-
methacin [19]. The stomachs were removed, opened along the
greater curvature and then scanned. The ulcer area (mm2) was
determined using AVSoft BioView.
2.3.7. Prostaglandin E2 (PGE2) assay
Rats were randomly divided into ﬁve groups (n = 7): sham,
vehicle, vehicle + indomethacin, ME (50 mg/kg) and ME (50 mg/
kg) + indomethacin. The +indomethacin groups subcutaneously re-
ceived indomethacin (a non-steroidal anti-inﬂammatory drug,
which inhibits the PGE2 synthesis) at 30 mg/kg, and the other
groups received vehicle. After 30 min, rats orally received vehicle
or ME. The sham group received neither drug nor treatment. After
Fig. 1. Gastric ulcer area (mm2) of rat stomachs with ethanol-induced gastric ulcers
after treatment with vehicle, carbenoxolone (100 mg/kg) or menthol (25, 50 or
100 mg/kg). The results are reported as the mean ± SEM. ANOVA followed by
Dunnett’s test, p < 0.01.
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Following stomach harvesting, the corpus was excised, weighed,
and suspended in 10 mM PBS at pH 7.4 (1 mL). The tissue was
minced ﬁnely with scissors and incubated at 37 C for 20 min. After
centrifugation at 9000g, the PGE2 levels in the supernatant were
measured by ELISA and read in spectrophotometer (420 nm) using
a commercial kit (R&D Systems, Minneapolis, USA). The results
were expressed as ng/mL [20].
2.3.8. Effect of menthol on castor oil-induced diarrhea
Three groups of rats were orally treated with vehicle (10 mL/kg),
loperamide hydrochloride (3 mg/kg) or ME (50 mg/kg). After 30min,
each rat received 1mL of castor oil orally. Immediately after ingesting
the castor oil, each ratwas kept in an individual cage, theﬂoorofwhich
was lined with blotting paper, and the rats were observed for 5 h. The
following parameters were then observed: onset of diarrhea, number
of solid, semi-solid, and watery feces, and total frequency of fecal out-
puts. Each rat received an evacuation index (EI) expressed according to
the formula: EI = 1 (number of solid stool) + 2 (number of semi-
solid stool) + 3 (number of watery stool) [21].
2.3.9. Effect of menthol on gastrointestinal motility
Rats were orally treated with vehicle (10 mL/kg), loperamide
hydrochloride (4 mg/kg) or ME (50 mg/kg). After 20 min, each rat
orally received 1 mL of charcoal meal (10% charcoal suspension
in 5% aqueous gum Arabic). After 30 min, rats were euthanized,
and the stomach and small intestine were removed. The distance
between the charcoal meal and the pylorus was measured and cor-
related to the distance from the pylorus to the caecum [22].
2.3.10. Acute toxicity
Male rats (n = 10) orally received vehicle or a single acute dose
of ME (500 mg/kg, corresponding to ten times the therapeutic
dose) after 12 h of fasting. Possible signs and symptoms associated
with toxicity were observed at 0, 30, 60, 120, 180 and 240 min after
the administration and then twice daily for the next 14 days. Body
weights were noted daily. At the end of the period, the rats were
euthanized, and the kidneys and liver were withdrawn, weighed
and evaluated. Biochemical analyses were performed on the rats’
serum to quantify AST (aspartate aminotransferase), ALT (alanine
aminotransferase), c-GT (gamma glutamyltransferase) and alka-
line phosphatase to evaluate liver damage and creatinine and urea
to evaluate kidney damage using the automated biochemical ana-
lyzer SBA-200, CELM, Brazil.
2.4. Statistical analysis
Parametric data were analyzed using an unpaired t-test or a
one-way analysis of variance (ANOVA) followed by Dunnett’s test
and compared to the vehicle group or Tukey’s test. The results were
presented as the mean ± standard error of the mean (SEM).
Nonparametric data (histology scoring) were analyzed using the
Kruskal–Wallis (nonparametric ANOVA) test, followed by a Dunn
multiple comparison test. The results were presented as the
median (range). All analyses were performed using GraphPad
InStat software. A value of p < 0.05 was considered signiﬁcant.
3. Results
3.1. Ethanol-induced gastric ulcers
3.1.1. Gastric ulcer area
The vehicle group presented several hemorrhagic bands that
were usually parallel to the long axis of the stomach, with an
average ulcer area of 374.82 ± 12.75 mm2. They were locatedmostly in the gastric corpus, and no visible lesions developed in
the non-secretory part of the stomach. The two highest ME doses
tested (i.e., 50 and 100 mg/kg) exhibited gastroprotective effects
(p < 0.01) when compared to the vehicle group. ME presented a
gastroprotective effect of 20.06% for the lower dose (25 mg/kg),
88.62% for 50 mg/kg (ulcer area 42.64 ± 15.64 mm2) and 98.42%
for the highest dose, 100 mg/kg (ulcer area 5.91 ± 5.33 mm2).
However, according to Tukey’s test, there was no difference
between the ulcer areas of the groups treated with 50 mg/kg or
100 mg/kg; therefore, the dose of 50 mg/kg was used for all subse-
quent experiments. The ulcer areas (mm2) are represented in Fig. 1.
3.1.2. Microscopic analyses
Microscopically, ME presented moderate epithelial desquama-
tion, mild hemorrhage, and glandular damage as well as an ab-
sence of eosinophilic inﬁltration, presenting a score of 3(1–3).
Carbenoxolone showed moderate epithelial desquamation and
glandular damage as well as mild hemorrhage and eosinophilic
inﬁltration, presenting a score of 4(2–5). The score of the vehicle
group was 12(11–12). The mucus polysaccharides were evidenced
after the PAS staining, which conferred a purple barrier covering
the gastric pits in the ME-treated rats. The HE and PAS staining
of the ulcers are displayed in Fig. 2.
3.2. Involvement of the NO/cGMP/K+ATP pathway in gastroprotection
In rats that were pre-treated with L-NAME (a NO-synthase
inhibitor) or ODQ (a guanylate cyclase inhibitor), the gastroprotec-
tive effect of ME (50 mg/kg) was maintained (62.65% and 97.71%
gastroprotection, respectively, compared to the vehicle-treated
group, p < 0.01), showing that the NO synthesis or cGMP were
not involved in the protective mechanism of ME. However, in rats
pretreated with glibenclamide (a K+ATP channel blocker), the gas-
troprotective effect of ME (50 mg/kg) was reversed, indicating
the involvement of K+ATP channels in gastroprotection (Table 1).
3.3. Involvement of NP-SH compounds or calcium channels in
gastroprotection
In rats pretreated with NEM (an NP-SH compound reagent), the
gastroprotective effect of ME (50 mg/kg) was reversed, indicating
the involvement of SH compounds in gastroprotection. However,
in rats that were pre-treated with verapamil (a calcium ion channel
blocker), the gastroprotective effect of ME (50 mg/kg) was main-
tained (a protective effect of 98.31% compared to the vehicle-trea-
ted group, p < 0.001), indicating that the calcium ion channels are
not involved in the gastroprotective mechanism of ME (Table 2).
Fig. 2. Photomicrography of rat stomachs with ethanol-induced gastric ulcers after treatment with (A, D) vehicle, (B, E) carbenoxolone (100 mg/kg) or (C, F) menthol (50 mg/
kg). In the HE staining (A, B, C), arrow head indicates epithelial desquamation and arrow indicates glandular damage. In the PAS staining (D, E, F), ⁄ indicates the mucus
secretion in the gastric glands.
Table 1
Effect of menthol (50 mg/kg) on ethanol-induced gastric ulcer area (mm2) in rats that were pretreated with L-NAME (NO
synthase inhibitor), ODQ (guanylate cyclase inhibitor) or glibenclamide (K+ATP channels blocker).
Pretreatment
(i.p)
Treatment (p.o) Ulcer area
(mm2)
Gastroprotection (%)
Vehicle Vehicle 501.70 ± 35.00 –
Menthol 50.52 ± 10.99⁄⁄⁄ 89.93
L-NAME 70 mg/kg Vehicle 476.44 ± 89.17 –
Menthol 177.94 ± 25.29⁄⁄ 62.65
ODQ 10 mg/kg Vehicle 652.54 ± 144.21 –
Menthol 14.94 ± 6.10⁄⁄ 97.71
Glibenclamide 3 mg/kg Vehicle 134.13 ± 16.03 –
Menthol 154.41 ± 28.50 0
The results are reported as the mean ± SEM. Unpaired t test, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
Table 2
Effect of menthol (50 mg/kg) on ethanol-induced gastric ulcer area (mm2) in rats that were pretreated with NEM (SH blocker) or verapamil
(calcium channel blocker).
Pretreatment (i.p) Treatment (p.o) Ulcer area (mm2) Gastroprotection (%)
Vehicle Vehicle 1825.62 ± 192.76 –
Menthol 17.86 ± 11.46⁄⁄⁄ 99.02
NEM 5mg/kg Vehicle 1799.24 ± 250.73 –
Menthol 1574.03 ± 346.59 8.34
Verapamil 5 mg/kg Vehicle 1155.17 ± 336.88 –
Menthol 19.53 ± 12.38⁄⁄ 98.31
The results are reported as the mean ± SEM. Unpaired t test, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
Table 3
Effect of menthol (50 mg/kg) on gastric juice parameters in rats with pyloric ligation.
Route Treatment Gastric juice volume (mL) [H+] mequiv/mL/4 h
Oral Vehicle 2.93 ± 0.36 9.60 ± 0.95
cimetidine 100 mg/kg 1.9 ± 0.13 2.23 ± 0.18⁄⁄
Menthol 50 mg/kg 3.39 ± 0.63 5.90 ± 0.67⁄⁄
Intraduodenal Vehicle 5.08 ± 0.21 10.23 ± 0.44
Cimetidine 100 mg/kg 2.42 ± 0.17⁄⁄ 4.62 ± 0.50⁄⁄
Menthol 50 mg/kg 2.95 ± 0.15⁄⁄ 9.05 ± 0.32
The results are reported as the mean ± SEM. ANOVA followed by Dunnett’s test, p < 0.01.
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A comparison of the gastric juice parameters of rats treated with
oral or intra-duodenal ME (50 mg/kg) demonstrated that the oraltreatmentwasable todiminish theH+ concentration (p < 0.01) in the
gastric juice without modifying its volume. The intra-duodenal
administration was not able to decrease the H+ concentration, but
it did diminish the volume of the gastric juice (Table 3).
Fig. 3. Quantiﬁcation of adherent mucus (lg/g of tissue) in the gastric mucosa of
rats treated with vehicle, carbenoxolone (200 mg/kg) or menthol (50 mg/kg). The
results are reported as the mean ± SEM. ANOVA followed by Dunnett0s test, p < 0.01.
Fig. 4. Gastric ulcer area (mm2) in rat stomachs with indomethacin-induced gastric
ulcers after treatment with vehicle, carbenoxolone (100 mg/kg) or menthol (50 mg/
kg). The results are reported as the mean ± SEM. ANOVA followed by Dunnett0s test,
compared to vehicle group, p < 0.01.
Fig. 5. PGE2 measurement (ng/mL) in the gastric mucosa of rats treated with
vehicle or menthol (50 mg/kg) alone or in association with nonselective COX
inhibitor (indomethacin). The results are reported as the mean ± SEM. ANOVA
followed by Dunnett’s test, compared to sham group, p < 0.01.
Table 4
Evacuation index and % of evacuation inhibition after oral treatment with vehicle,
loperamide hydrochloride (3 mg/kg) or menthol (50 mg/kg).
Treatment Evacuation index % of evacuation inhibition
Vehicle 13.0 ± 0.84 –
Loperamide 3 mg/kg 8.0 ± 1.0⁄⁄ 38.50
Menthol 50 mg/kg 8.3 ± 0.42⁄⁄ 36.15
The results are reported as the mean ± SEM. ANOVA followed by Dunnett’s test,
p < 0.01.
Table 5
Evaluation of intestinal motility (cm1/2) after oral treatment with vehicle, loperamide
hydrochloride (5 mg/kg) or menthol (50 mg/kg).
Treatment Intestinal motility % of motility inhibition
Vehicle 4.15 ± 0.31 –
Loperamide 5 mg/kg 1.91 ± 0.23⁄⁄ 53.97
Menthol 50 mg/kg 1.81 ± 0.32⁄⁄ 56.38
The results are reported as the mean ± SEM. ANOVA followed by Dunnett’s test,
p < 0.01.
Table 6
Effect of orally administered menthol (500 mg/kg) on rats’ body weight, organ weight,
and serum biochemical parameters.
Vehicle Menthol
Initial body weight (day 0) 196.70 ± 5.31 190.45 ± 4.54
Final body weight (day 14) 290.60 ± 8.29 272.67 ± 8.11
Kidneys weight 0.15 ± 0.00 0.15 ± 0.00
Liver weight 0.72 ± 0.02 0.70 ± 0.02
AST 105.80 ± 6.24 115.70 ± 7.44
ALT 46.90 ± 0.99 47.90 ± 1.00
Gama-GT 5.36 ± 0.46 5.09 ± 0.58
Alkaline phosphatase 295.00 ± 10.71 277.37 ± 14.30
Creatinine 0.28 ± 0.02 0.30 ± 0.03
Urea 45.30 ± 1.51 42.44 ± 1.20
Body weights are expressed in g. Organ weights are expressed in comparison to the
body weight (g1/2). AST, ALT, c-GT and alkaline phosphatase are expressed in U/L,
creatinine and urea are expressed in mg/dL. The results are reported as the
mean ± SEM. Unpaired t test.
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There was a 2.2-fold increase in the amount of gastric mucus
adhering to the stomach wall in the ME-treated (50 mg/kg) group
(3632.00 ± 66.06 lg/g, p < 0.01) compared to the vehicle-treated
group (1633.43 ± 43.73 lg/g) (Fig. 3).
3.6. Indomethacin-induced gastric ulcers
The vehicle-treated group had a large quantity of small
petechiae in the stomach and a mean ulcer area of38.06 ± 8.02 mm2. In this model, ME presented a gastroprotective
effect of 72.62% (ulcer area 10.42 ± 2.71 mm2, p < 0.01) in compar-
ison to the vehicle group (Fig. 4).3.7. PGE2 assay
The decreased level (p < 0.01) of PGE2 in the vehicle + indo-
methacin group, compared to that of the sham group, proves that
indomethacin induces decrease of PGE2 production. The ME groups
maintained PGE2 levels near that of the sham group, even with
indomethacin administration (Fig. 5).3.8. Effect of menthol on castor oil-induced diarrhea and
gastrointestinal motility
ME inhibited evacuation in 36.15% of the treated group com-
pared to the vehicle group (p < 0.01), indicating an antidiarrheal
activity comparable to the effect of the standard drug loperamide
hydrochloride (38.50%, Table 4). The antidiarrheal effect of ME
was connected to an antiperistaltic activity, decreasing the
intestinal motility in 56.18% of the treated animals compared to
the vehicle group (p < 0.01, Table 5).
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No signs or symptoms associated with toxicity were observed
on the day of oral administration or over the subsequent 14 days.
Body weights progressed normally. After the rats were euthanized,
there were no alterations in the macroscopic appearance of the
kidneys or liver or in their weights. There were no alterations in
the biochemical parameters analyzed in the rats’ serum between
the groups, indicating that there was no hepatotoxicity or nephro-
toxicity associated with the ME oral treatment (Table 6).4. Discussion
The present study investigated the gastroprotective activity of
()menthol (ME) in experimental models of gastric ulcer and
its possible mechanisms of action. In the ethanol-induced gastric
ulcer model, ME exhibited a dose-dependent effect and exerted
substantial protective action on the gastric mucosa. The lowest
effective dose (50 mg/kg) was used for all subsequent experiments.
Considering the multifactorial ways in which ethanol exerts its
ulcerogenic action, the possible mechanisms of gastroprotection
conferred by ME were investigated as follows.
The cellular perturbation caused by a damaging agent such as
ethanol disrupts the normal Ca2+ homeostasis. Ethanol adminis-
tration leads to an intracellular Ca2+ accumulation, providing an
injurious action in the gastric mucosa [23,24]. The oral administra-
tion of the calcium ion channel blocker verapamil was not able to
reverse the ME gastroprotective effect, indicating that the blockade
of the calcium ions efﬂux did not interfere with the protective
mechanism, and therefore, that this gastroprotective pathway is
not involved in ME activity.
Several studies have shown the importance of mucus secretion
in gastroprotection [8,25]. The mucus barrier is considered the ﬁrst
line ofmucosal defense because it decreases physical damage to the
epithelium by ingested foods. It is an important barrier against self-
digestion [26] and acts as an antioxidant, scavenging free radicals in
the mucosa [27]. Ulcerogenic substances cause disruptions in this
barrier and allow contact between the gastric juice and epithelial
cells, leading tomucosal injury [28]. Thus, the increased stimulation
of mucus production by 2.2-fold over the control group is a relevant
part of the hypothesized mechanism of gastric mucosal protection
by ME. The increase in mucus secretion was easily evidenced in
the photomicrographies of the PAS-stained gastric ulcer.
Endogenous NP-SH compounds helpmaintain the integrity of the
mucus barrier by uniting its subunits by disulﬁde bridges, preventing
the mucus from becoming soluble, and easily withdrawn by ulcero-
genic agents, including ethanol [29]. NP-SH compounds also prevent
the production of free radicals by ethanol and act as recycling antiox-
idants [30]. The rats that were pretreated with an inhibitor of NP-SH
compoundspresentedulcer areas similar to those of the vehicle-trea-
ted rats, indicating the importance of an intact NP-SH barrier to the
maintenance of the ME gastroprotective effect.
Mucus secretion also can be regulated by nitric oxide (NO) [31],
an endogenous gaseous mediator synthesized by the enzyme NO-
synthase (NOs). NO also plays key roles in enhancing blood ﬂow
[32], regulating acid secretion and inhibiting neutrophil aggrega-
tion [33] and leukocyte adherence to the vascular endothelium
[34]. Our results showed that despite the inhibition of NO synthe-
sis by the action of the NO-synthase inhibitor (L-NAME), ME ex-
erted a gastroprotection similar to that observed in the group
receiving ME treatment without NO blocking, indicating that main-
taining NO synthesis is not crucial to gastroprotection by ME.
In the gastric mucosa, NO interacts with neuropeptides and
prostaglandins to maintain mucosal integrity. NO activates gua-
nylyl cyclase to increase cyclic guanosine monophosphate (cGMP)levels and subsequently activates the ATP sensitive potassium
channels (K+ATP). The activation of this NO/cGMP/K+ATP pathway
leads to gastroprotection [35]. K+ATP channels mediate gastropro-
tection by enhancing gastric microcirculation and inhibiting
neutrophil activation and the subsequent superoxide production
[36]. Despite this mediation, there was no loss of gastroprotection
after the inhibition of NO synthesis or the cGMP blockade, but the
blockade of the K+ATP channels reversed the gastroprotective action
of ME, thus indicating the involvement of these channels in the
mechanism of action of ME.
K+ATP channels are not exclusively activated by the NO pathway
but can also be activated by PGE2 activity [37]. The oral treatment
with ME was able to maintain PGE2 levels, even after the adminis-
tration of the COX-inhibitor indomethacin, indicating the
importance of PGE2 in the mechanism of action of ME. This result
can explain the activation of the K+ATP channels as well as the
cytoprotective activity observed in the indomethacin-induced
gastric ulcer. Indomethacin, as a non-steroidal anti-inﬂammatory
drug (NSAID), induces gastric damage mainly by inhibiting prosta-
glandin production through inhibiting the activity of COX-1 and
COX-2 isozymes [38,39].
The physiological functions of PGE2 in the gastrointestinal tract
include stimulating bicarbonate and mucus secretion, maintaining
mucosal integrity, and inducing a trophic effect in gastric and
intestinal mucosa by triggering mitogenic signaling in mucosal
cells [40]. It is also known that PGE2 presents a strong anti-secre-
tory activity [41], which can, at least in part, explain the anti-secre-
tory effect observed after the oral administration of ME. The H+
concentration was decreased, but the gastric juice volume was
not altered. This effect did not occur in the intra-duodenally
treated rats, leading to the conclusion that ME acts via a local
rather than a systemic mechanism. In addition to the increasing
effect on PGE2 production, this antisecretory effect may also be
due to increased mucus secretion, as the mucus barrier is able to
neutralize secreted H+.
This study also evaluated ME activity in castor oil-induced
diarrhea and gastrointestinal motility. Experimentally, castor oil
induces diarrhea by increasing the secretion of ﬂuids and electro-
lytes in the intestinal lumen, thus resulting in ﬂuid accumulation
and in an aqueous content that ﬂows rapidly in the small and large
intestines [42]. In this assay, ME displayed signiﬁcant activity
against the diarrhea induced by castor oil, an effect that can be
compared to the standard drug loperamide. The antidiarrheal ef-
fect of ME was accompanied by an antiperistaltic effect. This is
an important pathway of gastroprotection, since the incidence of
gastric ulcers can be inﬂuenced by decreasing in gastric motility.
The relaxation of circular muscles in the stomach avoid the inci-
dence of ulcers through inducing the ﬂattening of the folds, which
leads to an increase in the mucosal area exposed to the necrotizing
agent and reduce the volume of the agent on the rugal crest [25].
The acute toxicity test did not show any signs of toxicity or
mortality. Behavioral changes such as irritation, restlessness, respi-
ratory distress, abnormal locomotion, and catalepsy were not ob-
served over a period of 14 days. There were no alterations in the
dosage of renal and hepatic enzymes or in body weight evolution,
revealing that ME has no toxicity when administered orally at a
dose of 500 mg/kg, which is ten times higher than the therapeutic
dose employed in this study.5. Conclusion
The results described here suggest that menthol presents anti-
ulcer activities against ethanol and indomethacin. The gastropro-
tective activity of menthol is associated mainly with mucus
secretion, which is related to the maintenance of NP-SH
278 A.L. Rozza et al. / Chemico-Biological Interactions 206 (2013) 272–278compounds, PGE2 production and K+ATP channel activation and to
an anti-secretory effect. Connected to the gastroprotective effect,
menthol also presents an antidiarrheal and antiperistaltic effect.
No signs of acute toxicity have been associated with the adminis-
tration of a high dose of menthol. However, further clinical and
toxicological studies must be conducted to support the use of
menthol as a potential antiulcerogenic drug.
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